Index heads for another dubious pivotal trial
Six years after failing phase III cobitolimod underwhelms in phase II, but Index ploughs on into a fresh pivotal study.
A blockbuster breast cancer niche has Roche and Sanofi in the lead
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
Asco-GU: confirmation for Seattle and a reminder for Mirati
Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
ACC preview: a veri important test for Merck and Bayer
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
Lilly spends big on mirikizumab
With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.
Asco-GU 2020: revving up for Peloton deal validation
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
VTV celebrates a double positive
Yesterday’s clinical study success has underlined VTV's status as a small-cap bet on Alzheibetes.
Perioperative use proves elusive for Tecentriq
Adjuvant and neoadjuvant settings are an important target for Roche’s Tecentriq, but how likely is the drug to become broadly applicable?
Another Alzheimer’s failure for Biogen bulls to shrug off
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.